CureVac N.V. Ordinary Shares
CVACCureVac N.V. is a biotechnology company focused on the development of mRNA-based therapeutics and vaccines. Founded in Germany, it aims to revolutionize medicine through innovative mRNA technology, with a focus on infectious diseases, cancer, and rare diseases.
Company News
BioNTech successfully met the minimum condition for its exchange offer to acquire CureVac, with 81.74% of CureVac shares tendered. The subsequent offering period will continue until December 18, 2025, allowing remaining shareholders to participate.
The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.
While smaller deals have been completed, including overseas acquisitions, the expected surge in large-scale mergers and acquisitions has not materialized. Factors like trade policy uncertainty and economic concerns have kept corporate decision-makers cautious about striking major deals.
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Nvidia gains as Q1 results, guidance top expectations; announces 10-1 split. Live Nation sinks 7% on report DOJ antitrust action is ready. Moderna, BioNTech close double-digits.
